BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12528092)

  • 1. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
    J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ; Zhang X; Zhu WL; Huang Y
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3.
    Tziakas D; Chalikias G; Parissis JT; Hatzinikolaou H; Stakos D; Papadopoulou E; Kortsaris A; Hatseras D
    Eur Cytokine Netw; 2004; 15(3):231-9. PubMed ID: 15542448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis.
    Jordán A; Roldán V; García M; Monmeneu J; de Burgos FG; Lip GY; Marín F
    J Intern Med; 2007 Sep; 262(3):385-92. PubMed ID: 17697160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
    Webb CS; Bonnema DD; Ahmed SH; Leonardi AH; McClure CD; Clark LL; Stroud RE; Corn WC; Finklea L; Zile MR; Spinale FG
    Circulation; 2006 Sep; 114(10):1020-7. PubMed ID: 16923753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.
    Hoheisel G; Sack U; Hui DS; Huse K; Chan KS; Chan KK; Hartwig K; Schuster E; Scholz GH; Schauer J
    Tuberculosis (Edinb); 2001; 81(3):203-9. PubMed ID: 11466032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction.
    Papadopoulos DP; Moyssakis I; Makris TK; Poulakou M; Stavroulakis G; Perrea D; Votteas VE
    Eur Cytokine Netw; 2005 Jun; 16(2):152-60. PubMed ID: 15941687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
    Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
    Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction.
    Wagner DR; Delagardelle C; Ernens I; Rouy D; Vaillant M; Beissel J
    J Card Fail; 2006 Feb; 12(1):66-72. PubMed ID: 16500583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR
    Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
    Tziakas DN; Chalikias GK; Parissis JT; Hatzinikolaou EI; Papadopoulos ED; Tripsiannis GA; Papadopoulou EG; Tentes IK; Karas SM; Chatseras DI
    Int J Cardiol; 2004 Apr; 94(2-3):269-77. PubMed ID: 15093992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.
    Bjerkeli V; Halvorsen B; Damås JK; Nordøy I; Yndestad A; Aukrust P; Frøland SS
    Ann Rheum Dis; 2004 Dec; 63(12):1659-63. PubMed ID: 15547092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Matrix metalloproteinases and their inhibitors in lung cancer with malignant pleural effusion].
    Moche M; Hui DS; Huse K; Chan KS; Choy DK; Scholz GH; Gosse H; Winkler J; Schauer J; Sack U; Hoheisel G
    Pneumologie; 2005 Aug; 59(8):523-8. PubMed ID: 16110415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
    J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
    Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
    Hsu CP; Huang CY; Wang JS; Sun PC; Shih CC
    Ann Thorac Surg; 2008 Oct; 86(4):1243-9. PubMed ID: 18805169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.